Abstract |
The anti- cancer effect of 5-fluorouracil (5-FU) is significantly affected by the intratumoral environment. Elevated expression of thymidylate synthase (TS), the target enzyme of 5-FU, and a lack of reduced folate or FdUMP results in insufficient inhibition of TS. Further, elevated expression of DPD in the tumor tissue results in a lack of FdUMP. TS-1, which contains tegafur and dihydroxypyridine (CDHP), a potent DPD inhibitor, is a promising anticancer drug. Isovorin has been available in Japan since autumn 1999. In cancer patients, folate deficiency may be derived from increased consumption and/or absorption disturbance of folate. In such situations, sufficient TS inhibition cannot be obtained if 5-FU is administered without supplementation of reduced folate. We describe in detail the metabolism of those substances in relation to the anticancer effect of 5-FU. Further, we show the theoretical construction of first-line and second-line chemotherapy with consideration of TS and DPD expression.
|
Authors | K Omura, K Kawakami, E Kanehira |
Journal | Gan to kagaku ryoho. Cancer & chemotherapy
(Gan To Kagaku Ryoho)
Vol. 28
Issue 1
Pg. 63-8
(Jan 2001)
ISSN: 0385-0684 [Print] Japan |
PMID | 11201382
(Publication Type: English Abstract, Journal Article)
|
Chemical References |
- Antimetabolites, Antineoplastic
- Antineoplastic Agents
- Thymidylate Synthase
- Cisplatin
- Fluorouracil
|
Topics |
- Antimetabolites, Antineoplastic
(pharmacology)
- Antineoplastic Agents
(pharmacology)
- Cisplatin
(pharmacology)
- Fluorouracil
(pharmacology)
- Gastrointestinal Neoplasms
(drug therapy, enzymology, pathology)
- Humans
- Thymidylate Synthase
(drug effects, metabolism)
|